Multiple pathways of cross-resistance to glycopeptides and daptomycin in persistent MRSA bacteraemia

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 11, 2015, Pages 2965-2972

  Chen, Chih Jung ^a,b   Huang, Yhu Chering ^a,b   Chiu, Cheng Hsu ^a,b  

^a CHANG GUNG CHILDREN S HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

DAPTOMYCIN; GLYCOPEPTIDE; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL GENOME; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIUM ISOLATE; CHEMOTHERAPY; CROSS RESISTANCE; DAPTOMYCIN RESISTANT STAPHYLOCOCCUS AUREUS; DELETION MUTANT; GENE EXPRESSION; GENE MAPPING; GENOTYPE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NEXT GENERATION SEQUENCING; NONHUMAN; PHENOTYPE; POINT MUTATION; STAPHYLOCOCCUS AUREUS; VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS; BACTEREMIA; DNA MUTATIONAL ANALYSIS; DNA SEQUENCE; DRUG EFFECTS; GENETIC SELECTION; HUMAN; ISOLATION AND PURIFICATION; MICROBIOLOGY; MOLECULAR EVOLUTION; MUTATION; STAPHYLOCOCCAL INFECTIONS;

ANTI-BACTERIAL AGENTS; BACTEREMIA; DAPTOMYCIN; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, BACTERIAL; EVOLUTION, MOLECULAR; GENOME, BACTERIAL; GLYCOPEPTIDES; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MUTATION; SELECTION, GENETIC; SEQUENCE ANALYSIS, DNA; STAPHYLOCOCCAL INFECTIONS;

EID: 84949008438     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv225     Document Type: Article

References (35)

1. Hawkins C, Huang J, Jin N et al. Persistent Staphylococcus aureus bacteremia: an analysis of risk factors and outcomes. Arch Intern Med 2007; 167: 1861-7.
2. Yoon YK, Kim JY, Park DW et al. Predictors of persistent methicillinresistant Staphylococcus aureus bacteraemia in patients treated with vancomycin. J Antimicrob Chemother 2010; 65: 1015-8.
3. Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 1991; 115: 674-80.
4. Murray KP, Zhao JJ, Davis SL et al. Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration >1 mg/L: a matched cohort study. Clin Infect Dis 2013; 56: 1562-9.
5. Kullar R, McKinnell JA, Sakoulas G. Avoiding the perfect storm: the biologic and clinical case for reevaluating the 7-day expectation for methicillin-resistant Staphylococcus aureus bacteremia before switching therapy. Clin Infect Dis 2014; 59: 1455-61.
6. Livermore DM. Future directions with daptomycin. J Antimicrob Chemother 2008; 62 Suppl 3: iii41-9.
7. Liu C, Bayer A, Cosgrove SE et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillinresistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52: e18-55.
8. Tenover FC, Sinner SW, Segal RE et al. Characterisation of a Staphylococcus aureus strain with progressive loss of susceptibility to vancomycin and daptomycin during therapy. Int J Antimicrob Agents 2009; 33: 564-8.
9. Cui L, Tominaga E, Neoh HM et al. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2006; 50: 1079-82.
10. Julian K, Kosowska-Shick K, Whitener C et al. Characterization of a daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus strain in a patient with endocarditis. Antimicrob Agents Chemother 2007; 51: 3445-8.
11. Shoji M, Cui L, Iizuka R et al. walK and clpP mutations confer reduced vancomycin susceptibility in Staphylococcus aureus. Antimicrob Agents Chemother 2011; 55: 3870-81.
12. Howden BP, Allen DL, Chua K et al. Evolution of multidrug resistance during Staphylococcus aureus infection involves mutation of the essential two component regulator WalKR. PLoS Pathog 2011; 7: e1002359.
13. Howden BP, Stinear TP, Allen DL et al. Genomic analysis reveals a point mutation in the two-component sensor gene graS that leads to intermediate vancomycin resistance in clinical Staphylococcus aureus. Antimicrob Agents Chemother 2008; 52: 3755-62.
14. Gardete S, Kim C, Hartmann BM et al. Genetic pathway in acquisition and loss of vancomycin resistance in a methicillin resistant Staphylococcus aureus (MRSA) strain of clonal type USA300. PLoS Pathog 2012; 8: e1002505.
15. Hafer C, Lin Y, Kornblum J et al. Contribution of selected gene mutations to resistance in clinical isolates of vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2012; 56: 5845-51.
16. Cafiso V, Bertuccio T, Purrello S et al. dltA overexpression: a strain-independent keystone of daptomycin resistance in methicillinresistant Staphylococcus aureus. Int J Antimicrob Agents 2014; 43: 26-31.
17. Kaito C, Sekimizu K. Colony spreading in Staphylococcus aureus. J Bacteriol 2007; 189: 2553-7.
18. Yang S-J, Mishra NN, Rubio A et al. Causal role of single nucleotide polymorphisms within the mprF gene of Staphylococcus aureus in daptomycin resistance. Antimicrob Agents Chemother 2013; 57: 5658-64.
19. Rumble SM, Lacroute P, Dalca AV et al. SHRiMP: accurate mapping of short color-space reads. PLoS Comput Biol 2009; 5: e1000386.
20. Chen C-J, Lin M-H, Shu J-C et al. Reduced susceptibility to vancomycin in isogenic Staphylococcus aureus strains of sequence type 59: tracking evolution and identifying mutations by whole-genome sequencing. J Antimicrob Chemother 2014; 69: 349-54.
21. Wootton M, Howe RA, Hillman R et al. A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J Antimicrob Chemother 2001; 47: 399-403.
22. Yang S-J, Kreiswirth BN, Sakoulas G et al. Enhanced expression of dltABCD is associated with the development of daptomycin nonsusceptibility in a clinical endocarditis isolate of Staphylococcus aureus. J Infect Dis 2009; 200: 1916-20.
23. Dubrac S, Bisicchia P, Devine KM et al. A matter of life and death: cell wall homeostasis and the WalKR (YycGF) essential signal transduction pathway. Mol Microbiol 2008; 70: 1307-22.
24. Mwangi MM,Wu SW, Zhou Y et al. Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. Proc Natl Acad Sci USA 2007; 104: 9451-6.
25. Mukhopadhyay K, Whitmire W, Xiong YQ et al. In vitro susceptibility of Staphylococcus aureus to thrombin-induced platelet microbicidal protein-1 (tPMP-1) is influenced by cell membrane phospholipid composition and asymmetry. Microbiology 2007; 153: 1187-97.
26. Peschel A, Jack RW, Otto M et al. Staphylococcus aureus resistance to human defensins and evasion of neutrophil killing via the novel virulence factor MprF is based on modification of membrane lipids with L-lysine. J Exp Med 2001; 193: 1067-76.
27. Jones T, Yeaman MR, Sakoulas G et al. Failures in clinical treatment of Staphylococcus aureus infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding. Antimicrob Agents Chemother 2008; 52: 269-78.
28. Humphries RM, Pollett S, Sakoulas G. A current perspective on daptomycin for the clinical microbiologist. Clin Microbiol Rev 2013; 26: 759-80.
29. Mishra NN, Bayer AS. Correlation of cell membrane lipid profiles with daptomycin resistance in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2013; 57: 1082-5.
30. Ernst CM, Staubitz P, Mishra NN et al. The bacterial defensin resistance protein MprF consists of separable domains for lipid lysinylation and antimicrobial peptide repulsion. PLoS Pathog 2009; 5: e1000660.
31. Szurmant H, Bu L, Brooks CL, Hoch JA. An essential sensor histidine kinase controlled by transmembrane helix interactions with its auxiliary proteins. Proc Natl Acad Sci USA 2008; 105: 5891-6.
32. Jang H-C, Kim S-H, Kim KH et al. Salvage treatment for persistent methicillin-resistant Staphylococcus aureus bacteremia: efficacy of linezolid with or without carbapenem. Clin Infect Dis 2009; 49: 395-401.
33. Park HJ, Kim S-H, Kim M-J et al. Efficacy of linezolid-based salvage therapy compared with glycopeptide-based therapy in patients with persistent methicillin-resistant Staphylococcus aureus bacteremia. J Infect 2012; 65: 505-12.
34. van Hal SJ, Steen JA, Espedido BA et al. In vivo evolution of antimicrobial resistance in a series of Staphylococcus aureus patient isolates: the entire picture or a cautionary tale? J Antimicrob Chemother 2014; 69: 363-7.
35. Dhand A, Sakoulas G. Daptomycin in combination with other antibiotics for the treatment of complicated methicillin-resistant Staphylococcus aureus bacteremia. Clin Ther 2014; 36: 1303-16.